Chemotherapy dose reduction and delay in clinical practiceevaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer

European Journal of Cancer

Volumn 36, Issue SUPPL. 1, 2000, Pages 11-14

  Chang, J ^a  

^a LAKERIDGE HEALTH CORPORATION   (Canada)

Author keywords

Adjuvant chemotherapy; Breast cancer; Chemotherapy dose delay; Chemotherapy dose reduction; Neutropenia

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; DATA BASE; DRUG ADMINISTRATION; DRUG DOSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NEUTROPENIA; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL TIME; TREATMENT OUTCOME;

EID: 0033997961     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00259-2     Document Type: Article

References (14)

1. Parker SL, Tong T, Bolden S, et al. Cancer statistics, 1997. CA Cancer J Clin 1997, 47, 5-27.
2. Anonymous. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women. Early Breast Cancer Trialists' Collaborative Group. N Engl J Med 1988, 319, 1681-1692.
3. Anonymous. Ovarian ablation in early breast cancer: overview of the randomized trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1996, 348, 1189-1196.
4. Gelber RD, Cole BF, Goldhirsch A, et al. Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for post-menopausal breast cancer: meta-analysis of quality-adjusted survival. Lancet 1996, 347, 1066-1071.
5. The Steering Committee. Clinical practice guidelines for the care and treatment of breast cancer: a Canadian consensus document. Can Med Assoc J 1998, 158(Suppl).
6. Bonadonna G, Valagussa P, Moliterni A, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995, 332, 901-906.
7. Wood WC, Budman DR, Korun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node positive breast carcinoma. N Engl J Med 1994, 330(18), 1253-1259.
8. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst 1998, 90, 1205-1211.
9. Levine MN, Bramwell VH, Pritchard KI, et al. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998, 16, 2651-2658.
10. Goldhirsch A, Gelber RD. Understanding adjuvant chemotherapy for breast cancer. N Engl J Med 1994, 330, 1308-1309.
11. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984, 2, 1281-1288.
12. Smith GA, Fine MJ, Lenert LL, Newbold RC. Project Chemo-Insight reveals physician practice patterns for adjuvant breast cancer chemotherapy, and compares the dose intensity of CMF, AC, and CAF. Proc Am Soc Clin Oncol 1999, 18, 78a (abstract 296).
13. Silber JH, Fridman M, DiPaola RS, et al. First-cycle blood counts and subsequent neutropenia, dose reduction, or delay in early-stage breast cancer therapy. J Clin Oncol 1998, 16, 2392-2400.
14. Silber JH, Fridman M, Shpilsky A, et al. Modeling the cost-effectiveness of granulocyte colony-stimulating factor use in early-stage breast cancer. J Clin Oncol 1998, 16, 2435-2444.